Matt Kalaycio is an Oncology physician affiliated with Cleveland Clinic. OpenAlex indexes 625 publications with 8,773 citations (h-index 43); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9500 Euclid Ave
Cleveland, OH 441950001
Telephone
800-223-2273Registry record last updated 11 Feb 2008.
Clinical trials
- Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Sponsor: Case Comprehensive Cancer Center
- S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment
Sponsor: SWOG Cancer Research Network
- Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Sponsor: The Cleveland Clinic
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Rigel Pharmaceuticals, Inc.Program year20241 payment
- Genmab U.S., Inc.Program year20232 payments
- Novartis Pharmaceuticals CorporationProgram year20213 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
49.3%Kinase inhibitor31.4%Jakafi28%Imatinib Mesylate16%Calquence16%Imbruvica11%Sprycel11%Brukinsa7%Bosulif6%Tasigna6%Part D<11 patientsBCL-2 Inhibitor9.3%Venclexta100%Part D<11 patients+ 2 more classes in this area
Dermatology
22.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor22.1%Acyclovir100%Part D≥30 patientsNervous system
7.7%SSRI3.7%Trazodone Hcl54%Escitalopram Oxalate46%Part D<11 patientsGabapentinoids2.2%Gabapentin100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Samir Kapadia, MD
Cleveland Clinic
Lars Svensson, MD
Cleveland Clinic
Mina Chung, MD
Cleveland Clinic
Gene Barnett, MD
Cleveland Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”